Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 20,000 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 20,000 shares of Travere Therapeutics stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $45.00, for a total value of $900,000.00. Following the transaction, the insider directly owned 111,473 shares of the company’s stock, valued at $5,016,285. The trade was a 15.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The stock was sold at an average price of $43.95, for a total value of $13,668.45.
• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The stock was sold at an average price of $46.65, for a total value of $101,417.10.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Stock Performance

NASDAQ:TVTX opened at $44.70 on Thursday. The business has a 50 day moving average of $32.59 and a 200 day moving average of $32.83. The company has a market capitalization of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $48.61. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The company had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.Travere Therapeutics’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.47) EPS. On average, sell-side analysts predict that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TVTX. Wedbush boosted their price objective on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price objective for the company in a research report on Tuesday, April 14th. Guggenheim boosted their price objective on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Citigroup boosted their price objective on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $47.83.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Travere Therapeutics by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock valued at $1,029,000 after acquiring an additional 6,831 shares in the last quarter. Norges Bank purchased a new stake in Travere Therapeutics in the second quarter worth $1,051,000. First Trust Advisors LP purchased a new stake in Travere Therapeutics in the second quarter worth $3,538,000. Cresset Asset Management LLC grew its stake in Travere Therapeutics by 26.5% in the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock worth $427,000 after purchasing an additional 6,047 shares during the period. Finally, Qube Research & Technologies Ltd grew its stake in Travere Therapeutics by 106.2% in the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after purchasing an additional 311,137 shares during the period.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year‑over‑year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long‑term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre‑arranged Rule 10b5‑1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500‑share sale) can create short‑term selling pressure or investor concern. Example SEC filing: CEO Form 4

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.